– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...